FORMULATION OF TOCILIZUMAB AND METHOD FOR TREATING COVID-19 BY INHALATION

FORMULATION OF TOCILIZUMAB AND METHOD FOR TREATING COVID-19 BY INHALATION

The present invention is directed to formulations containing the anti-IL-6 therapeutic monoclonal antibody tocilizumab and pharmaceutically acceptable excipients that can be administered using a soft mist inhaler or a nebulizer. La présente invention concerne des formulations contenant l'antico...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: MANGUKIYA, Hitesh, HUANG, Cai Gu
Format: Patent
Sprache:eng ; fre
Schlagworte:
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator MANGUKIYA, Hitesh
HUANG, Cai Gu
description The present invention is directed to formulations containing the anti-IL-6 therapeutic monoclonal antibody tocilizumab and pharmaceutically acceptable excipients that can be administered using a soft mist inhaler or a nebulizer. La présente invention concerne des formulations contenant l'anticorps monoclonal thérapeutique anti-IL-6 tocilizumab et des excipients pharmaceutiquement acceptables qui peuvent être administrés à l'aide d'un inhalateur brumisateur ou d'un nébuliseur.
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_WO2022006051A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>WO2022006051A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_WO2022006051A13</originalsourceid><addsrcrecordid>eNrjZPB08w_yDfVxDPH091Pwd1MI8Xf29PGMCvV1dFJw9HNR8HUN8fB3UQCqUggJcgUq83NXcPYP83TRNbRUcIpU8PTzcITo5mFgTUvMKU7lhdLcDMpuriHOHrqpBfnxqcUFicmpeakl8eH-RgZGRgYGZgamho6GxsSpAgDQkC2z</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>FORMULATION OF TOCILIZUMAB AND METHOD FOR TREATING COVID-19 BY INHALATION</title><source>esp@cenet</source><creator>MANGUKIYA, Hitesh ; HUANG, Cai Gu</creator><creatorcontrib>MANGUKIYA, Hitesh ; HUANG, Cai Gu</creatorcontrib><description>The present invention is directed to formulations containing the anti-IL-6 therapeutic monoclonal antibody tocilizumab and pharmaceutically acceptable excipients that can be administered using a soft mist inhaler or a nebulizer. La présente invention concerne des formulations contenant l'anticorps monoclonal thérapeutique anti-IL-6 tocilizumab et des excipients pharmaceutiquement acceptables qui peuvent être administrés à l'aide d'un inhalateur brumisateur ou d'un nébuliseur.</description><language>eng ; fre</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><creationdate>2022</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20220106&amp;DB=EPODOC&amp;CC=WO&amp;NR=2022006051A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20220106&amp;DB=EPODOC&amp;CC=WO&amp;NR=2022006051A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>MANGUKIYA, Hitesh</creatorcontrib><creatorcontrib>HUANG, Cai Gu</creatorcontrib><title>FORMULATION OF TOCILIZUMAB AND METHOD FOR TREATING COVID-19 BY INHALATION</title><description>The present invention is directed to formulations containing the anti-IL-6 therapeutic monoclonal antibody tocilizumab and pharmaceutically acceptable excipients that can be administered using a soft mist inhaler or a nebulizer. La présente invention concerne des formulations contenant l'anticorps monoclonal thérapeutique anti-IL-6 tocilizumab et des excipients pharmaceutiquement acceptables qui peuvent être administrés à l'aide d'un inhalateur brumisateur ou d'un nébuliseur.</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2022</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZPB08w_yDfVxDPH091Pwd1MI8Xf29PGMCvV1dFJw9HNR8HUN8fB3UQCqUggJcgUq83NXcPYP83TRNbRUcIpU8PTzcITo5mFgTUvMKU7lhdLcDMpuriHOHrqpBfnxqcUFicmpeakl8eH-RgZGRgYGZgamho6GxsSpAgDQkC2z</recordid><startdate>20220106</startdate><enddate>20220106</enddate><creator>MANGUKIYA, Hitesh</creator><creator>HUANG, Cai Gu</creator><scope>EVB</scope></search><sort><creationdate>20220106</creationdate><title>FORMULATION OF TOCILIZUMAB AND METHOD FOR TREATING COVID-19 BY INHALATION</title><author>MANGUKIYA, Hitesh ; HUANG, Cai Gu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_WO2022006051A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre</language><creationdate>2022</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><toplevel>online_resources</toplevel><creatorcontrib>MANGUKIYA, Hitesh</creatorcontrib><creatorcontrib>HUANG, Cai Gu</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>MANGUKIYA, Hitesh</au><au>HUANG, Cai Gu</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>FORMULATION OF TOCILIZUMAB AND METHOD FOR TREATING COVID-19 BY INHALATION</title><date>2022-01-06</date><risdate>2022</risdate><abstract>The present invention is directed to formulations containing the anti-IL-6 therapeutic monoclonal antibody tocilizumab and pharmaceutically acceptable excipients that can be administered using a soft mist inhaler or a nebulizer. La présente invention concerne des formulations contenant l'anticorps monoclonal thérapeutique anti-IL-6 tocilizumab et des excipients pharmaceutiquement acceptables qui peuvent être administrés à l'aide d'un inhalateur brumisateur ou d'un nébuliseur.</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language eng ; fre
recordid cdi_epo_espacenet_WO2022006051A1
source esp@cenet
subjects HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
title FORMULATION OF TOCILIZUMAB AND METHOD FOR TREATING COVID-19 BY INHALATION
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T00%3A46%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=MANGUKIYA,%20Hitesh&rft.date=2022-01-06&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EWO2022006051A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true